神戸大学附属図書館デジタルアーカイブ
https://hdl.handle.net/20.500.14094/0100486144

このアイテムのアクセス数:25件（2024-07-04 06:20 集計）

閲覧可能ファイル 

ファイル フォーマット サイズ 閲覧回数 説明
0100486144 (fulltext) pdf 475 KB 37

メタデータ

ファイル出力

メタデータID
0100486144
アクセス権
open access
出版タイプ
Version of Record
タイトル
Effectiveness and Safety of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in Pulmonary Sarcomatoid Carcinoma
著者
Hazama, Daisuke ; Nakahama, Kenji ; Kodama, Hiroaki ; Miyazaki, Akito ; Azuma, Koichi ; Kawashima, Yosuke ; Sato, Yuki ; Ito, Kentaro ; Shiraishi, Yoshimasa ; Miura, Keita ; Takahama, Takayuki ; Oizumi, Satoshi ; Namba, Yoshinobu ; Ikeda, Satoshi ; Yoshioka, Hiroshige ; Tsuya, Asuka ; Yasuda, Yuichiro ; Negi, Yoshiki ; Hara, Ayako ; Toda, Michihito ; Tachihara, Motoko
著者ID
A2841
研究者ID
1000030894604
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=35536a2922286287520e17560c007669
著者名
Hazama, Daisuke
羽間, 大祐
ハザマ, ダイスケ
所属機関名
医学部附属病院
著者名
Nakahama, Kenji
著者名
Kodama, Hiroaki
著者名
Miyazaki, Akito
著者名
Azuma, Koichi
著者名
Kawashima, Yosuke
著者名
Sato, Yuki
著者名
Ito, Kentaro
著者名
Shiraishi, Yoshimasa
著者名
Miura, Keita
著者名
Takahama, Takayuki
著者名
Oizumi, Satoshi
著者名
Namba, Yoshinobu
著者名
Ikeda, Satoshi
著者名
Yoshioka, Hiroshige
著者名
Tsuya, Asuka
著者名
Yasuda, Yuichiro
著者名
Negi, Yoshiki
著者名
Hara, Ayako
著者名
Toda, Michihito
著者ID
A1452
研究者ID
1000040448626
KUID
https://kuid-rm-web.ofc.kobe-u.ac.jp/search/detail?systemId=8a84f5066adebfb6520e17560c007669
著者名
Tachihara, Motoko
立原, 素子
タチハラ, モトコ
所属機関名
医学研究科
収録物名
JTO Clinical and Research Reports
巻(号)
5(1)
ページ
100613
出版者
Elsevier
刊行日
2024-01
公開日
2024-01-12
抄録
Introduction: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of lung cancer associated with poor prognosis and resistance to conventional chemotherapy. Immune checkpoint inhibitors (ICIs), alone or in combination with chemotherapy, were found to have clinical benefits in PSC in recent studies. Nevertheless, because these studies included a small number of patients owing to disease rarity, larger studies are needed to evaluate the effectiveness and safety of ICI-based therapy for PSC. Methods: This multicenter retrospective study evaluated patients with ICI-naive advanced or metastatic PSC who were treated with ICI-based therapy at 25 hospitals in Japan. Results: A total of 124 patients were evaluated. The overall response rate, median progression-free survival (PFS), and median overall survival (OS) were 59.0%, 10.5 months, and 32.8 months, respectively. The PFS and OS rates at 24 months were 35.3% and 51.5%, respectively. Programmed death-ligand 1 expression, concomitant chemotherapy, and the treatment line were not significantly associated with PFS or OS. Immune-related adverse events (irAEs) were observed in 70 patients (56.5%), including 30 (24.2%) with grade 3 to 5 events. Patients with mild irAEs (grades 1–2) had longer PFS and OS than did those with severe (grades 3–5) or no irAEs. In a multivariate analysis, any-grade irAEs and the absence of liver metastases were independently associated with PFS, whereas any-grade irAEs and Eastern Cooperative Oncology Group performance status less than or equal to 1 were independently associated with OS. Conclusions: ICI-based therapy was found to have promising effectiveness in patients with advanced or metastatic PSC, regardless of programmed death-ligand 1 expression, concomitant chemotherapy, or treatment line.
キーワード
Pulmonary sarcomatoid carcinoma
Immune checkpoint inhibitors
Real-world data
Lung cancer
カテゴリ
医学研究科
医学部附属病院
学術雑誌論文
権利
© 2023 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.
CC license
This is an open access article under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International license